Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

CLEC2A, a validated cancer-specific antigen, is an ideal candidate for immunotherapeutic targeting in KMT2A-rearranged AML

Danielle Kirkey, Corinne Summers, Katherine Tarlock, Benjamin Huang, Grace Hawkins, Nika Panahi, Melia Blankenfeld, Isabel Lira, Bruce Liu, Seungmin Shin, Rhonda Ries, Jack H. Peplinski, Simona Manni, Pamela De Falco, Biagio De Angelis, Concetta Quintarelli, Franco Locatelli, Wei Li, Soheil Meshinchi

Blood (2025) 146 (Supplement 1): 4123.

https://doi.org/10.1182/blood-2025-4123

Published: 2025

Journal Articles

Fratricide-resistant anti-CD7 CAR-T cells for relapsed/refractory Acute Myeloid Leukemia

Marco Becilli, Chiara Rosignoli, Francesca Del Bufalo, Pietro Merli, Mattia Algeri, Daria Pagliara, Francesco Quagliarella, Federica Galaverna, Valentina Bertaina, Maria Giuseppina Cefalo, Clelia Geraci, Giovanna Del Principe, Biagio De Angelis, Chiara Agrati, Concetta Quintarelli, Soheil Meshinchi, Dario Campana, Franco Locatelli

Blood (2025) 146 (Supplement 1): 6946.

https://doi.org/10.1182/blood-2025-6946

Published: 2025

Journal Articles

Phase I study of FH FOLR1 CAR T for pediatric patients with FOLR1+/CBFA2T3::GLIS2+ relapsed or refractory Acute Myeloid Leukemia

Katherine Tarlock, Corinne Summers, Danielle Kirkey, Rhonda Ries, Maria Pardo, Andrew Menssen, Chad Hudson, Folashade Otegbeye, Lara Kropp, Christy Greene, Stefanie Schmuck, Armenuhi Avanesyan, Concetta Quintarelli, Michael Loken, Franco Locatelli, Soheil Meshinchi

Blood (2025) 146 (Supplement 1): 4176.

https://doi.org/10.1182/blood-2025-4176

Published: 2025

Journal Articles

A novel B7-H3-specific binder enables effective CAR T-cell therapy in an Acute Myeloid Leukemia experimental model

Pamela De Falco, Alessio Ottaviani, Michele Veneruso, Marilena Margiotta, Simona Manni, Marika Guercio, Francesca Del Bufalo, Roberta Castriconi, Cristina Bottino, Danielle Kirkey, Soheil Meshinchi, Pietro Merli, Marco Becilli, Biagio De Angelis, Concetta Quintarelli, Franco Locatelli

Blood (2025) 146 (Supplement 1): 6095.

https://doi.org/10.1182/blood-2025-6095

Published: 2025

Journal Articles

CD19 antigen: From tumor target to safety switch able to improve the safety profile of CAR T cell therapy

Simona Manni, Laura Iaffaldano, Maria Cecilia Quadraccia, Mariasole Aurigemma, Marika Guercio, Simona Caruso, Maria Antonietta De Ioris, Giada Del Baldo, Danielle Kirkey, Soheil Meshinchi, Pietro Merli, Marco Becilli, Francesca Del Bufalo, Biagio De Angelis, Franco Locatelli, Concetta Quintarelli

Blood (2025) 146 (Supplement 1): 2541.

https://doi.org/10.1182/blood-2025-2541

Published: 2025

Journal Articles

Effective Dual Targeting of PRAME and WT1 with CD33-Gated ARTEMIS® Antibody-TCR Platform in Acute Myeloid Leukemia

Melia Blankenfeld, Danielle C. Kirkey, Guangyan Xiong, Hongbing Zhang, Grace Hawkins, Isabel Lira, Cyd McKay, Christina Root, Concetta Quintarelli, Franco Locatelli, Cheng Liu, Soheil Meshinchi

Blood (2024) 144 (Supplement 1): 3417.

https://doi.org/10.1182/blood-2024-206204

Published: 2024

Journal Articles

Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A

Danielle C. Kirkey, Grace Hawkins, Melia Blankenfeld, Isabel Lira, Nika Panahi, Margaret G Hines, Seungmin Shin, Tiffany Hylkema, Cyd McKay, Christina Root, Logan K. Wallace, Jack H. Peplinski, Rhonda E. Ries, Concetta Quintarelli, Franco Locatelli, Wei Li, Soheil Meshinchi

Blood (2024) 144 (Supplement 1): 2050.

https://doi.org/10.1182/blood-2024-212075

Published: 2024

Journal Articles

Phase I/II Clinical Trial on CD19-Chimeric Antigen Receptor (CAR) T Cells Generated with an Automated Process, from Fresh Apheresis, and Reinfused As Fresh Drug Product for Pediatric/Young Adult Patients with Relapsed/Refractory (r/r) B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Francesca Del Bufalo, Mattia Algeri, Daria Pagliara, Linda Hanssens, Valentina Bertaina, Monica Gunetti, Giuseppina Li Pira, Chiara Rosignoli, Michele Massa, Matilde Sinibaldi, Giovanna Leone, Marco Becilli, Biagio De Angelis, Concetta Quintarelli, Franco Locatelli

Blood (2024) 144 (Supplement 1): 4834.

https://doi.org/10.1182/blood-2024-206901

Published: 2024

Journal Articles

CD7.Pebl-CART for Patients with Relapsed/Refractory (r/r) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Marco Becilli, Francesca Del Bufalo, Pietro Merli, Daria Pagliara, Chiara Rosignoli, Valentina Bertaina, Giuseppina Li Pira, Maria Giuseppina Cefalo, Monica Gunetti, Stefano Iacovelli, Emilia Boccieri, Matilde Sinibaldi, Yunqin Lee, Concetta Quintarelli, Dario Campana, Franco Locatelli

Blood (2024) 144 (Supplement 1): 4830.

https://doi.org/10.1182/blood-2024-203443

Published: 2024

Journal Articles

Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia

Isabel Lira, Danielle C. Kirkey, Marilena Nicolaidou, Henrike Muller, Marta Barisa, Melia Blankenfeld, Grace Hawkins, Cyd McKay, Christina Root, Laura Pardo, Michael R. Loken, Tiffany Hylkema, Concetta Quintarelli, Franco Locatelli, John Anderson, Soheil Meshinchi

Blood (2024) 144 (Supplement 1): 4793.

https://doi.org/10.1182/blood-2024-206227

Published: 2024

Journal Articles

Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL

Blood (2023) 142 (2): 146–157.

https://doi.org/10.1182/blood.2023020023

Published: 2023

Includes: Supplemental data

Journal Articles

CAR.CD123-NK Cells Have an Equally Effective but Safer Off-Tumor/on-Target Profile As Compared to CARCD123-T Cells for the Treatment of Acute Myeloid Leukaemia

Blood (2022) 140 (Supplement 1): 7369–7370.

https://doi.org/10.1182/blood-2022-166107

Published: 2022

Journal Articles

Academic, Phase I/II Trial on T Cells Expressing a Second Generation, CD19-Specific Chimeric Antigen Receptor (CAR) and Inducible Caspase 9 Safety Switch for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children

Francesca Del Bufalo, MD, Concetta Quintarelli, PhD, Biagio De Angelis, PhD, Ignazio Caruana, PhD, Matilde Sinibaldi, PhD, Luciana Vinti, MD, Pietro Merli, MD, Mattia Algeri, MD, Annalisa Ruggeri, MD, Federica Galaverna, MD, Valentina Cirillo, PhD, Maria Giuseppina Cefalo, MD, Giuseppina Li Pira, PhD, Giovanna Leone, MD, Valentina Bertaina, PhD, Franca Fassio, PhD, Monica Gunetti, PhD, Stefano Iacovelli, PhD, Franco Locatelli, MD PhD

Blood (2019) 134 (Supplement_1): 1341.

https://doi.org/10.1182/blood-2019-129821

Published: 2019

Journal Articles

A New Promising Third Generation CAR-CD30 T-Cell Therapy for CD30+ Lymphoma

Blood (2019) 134 (Supplement_1): 2069.

https://doi.org/10.1182/blood-2019-127969

Published: 2019

Journal Articles

CD19 Redirected CAR NK Cells Are Equally Effective but Less Toxic Than CAR T Cells

Concetta Quintarelli, PhD, Simona Sivori, PhD, Simona Caruso, PhD, Simona Carlomagno, PhD, Iolanda Boffa, PhDstudent, Domenico Orlando, PhDstudent, Marika Guercio, Biancamaria Cembrola, PhD, Angela Pitisci, Stefano Di Cecca, PhD, Giuseppina Li Pira, PhD, Luciana Vinti, MD, Biagio De Angelis, PhD, Lorenzo Moretta, MD PhD, Franco Locatelli

Blood (2018) 132 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2018-99-118005

Published: 2018

Journal Articles

Alpha/Beta T-Cell and B-Cell Depletion HLA-Haploidentical Hematopoietic Stem Cell Transplantation Is an Effective Treatment for Children/Young Adults with Acute Leukemia

Pietro Merli, MD, Mattia Algeri, MD, Giuseppina Li Pira, PhD, Michela Falco, PhD, Daniela Pende, PhD, Valentina Bertaina, Daria Pagliara, MD PhD, Federica Galaverna, MD, Annalisa Ruggeri, MD PhD, Concetta Quintarelli, PhD, Lorenzo Moretta, MD PhD, Alice Bertaina, MD PhD, Franco Locatelli

Blood (2018) 132 (Supplement 1): 2169.

https://doi.org/10.1182/blood-2018-99-117136

Published: 2018

Journal Articles

Patient-Derived Chimeric Antigen Receptor T-Cell Production Based on a Gammaretroviral Vector Platform Is Not Associated with Generation of CAR+ Leukemia Blasts

Concetta Quintarelli, PhD, Iolanda Boffa, PhDstudent, Matilde Sinibaldi, Domenico Orlando, PhDstudent, Marika Guercio, Stefano Di Cecca, PhD, Simona Caruso, PhD, Angela Pitisci, Valentina Bertaina, Francesca Del Bufalo, MD, Pietro Merli, MD, Mattia Algeri, MD, Federica Galaverna, MD, Luciana Vinti, MD, Giuseppina Li Pira, PhD, Biagio De Angelis, PhD, Franco Locatelli

Blood (2018) 132 (Supplement 1): 2204.

https://doi.org/10.1182/blood-2018-99-119413

Published: 2018

Journal Articles

Phase I-IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in Relapsed/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

Matteo Giovanni Carrabba, MD, Monica Casucci, PhD, Michael Hudecek, MD, Concetta Quintarelli, PhD, Javier Briones, MD, Roman Hajek, MD PhD, Jorge Sierra, MD, Franco Locatelli, Hermann Einsele, MD PhD, Claudio Bordignon, MD, Fabio Ciceri, MD, Catia Traversari, PhD

Blood (2018) 132 (Supplement 1): 5790.

https://doi.org/10.1182/blood-2018-99-117974

Published: 2018

Journal Articles

T-Cell Depleted HLA-Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT) Followed By Donor Lymphocyte Infusion with T Cells Transduced with the Inducible Caspase 9 (iC9) Suicide Gene in Children with Hematological Malignancies

Barbarella Lucarelli, MD, Alice Bertaina, MD PhD, Pietro Merli, MD, Concetta Quintarelli, PhD, Daniela Pende, MD, Michela Falco, PhD, Maria Giuseppina Cefalo, MD, Giuseppina Li Pira, PhD, Ignazio Caruana, PhD, Letizia Pomponia Brescia, MD, Luisa Strocchio, MD, Giuseppe Maria Milano, MD, Valentina Bertaina, PhD, Matilde Sinibaldi, PhD, Mattia Algeri, MD, Lorenzo Moretta, MD, Joanna Stanson, Annemarie Moseley, MD PhD, Franco Locatelli, MD

Blood (2016) 128 (22): 4683.

https://doi.org/10.1182/blood.V128.22.4683.4683

Published: 2016

Journal Articles

Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Results of a Phase I-II Trial

Franco Locatelli, Prof, MD PhD, Pietro Merli, MD, Giuseppina Li Pira, PhD, Valentina Bertaina, PhD, Barbarella Lucarelli, MD, Letizia Pomponia Brescia, MD, Mauro Montanari, MD, Daniela Pende, MD, Michela Falco, PhD, Daria Pagliara, MD, Maria Giuseppina Cefalo, MD, Alessandro Moretta, MD, Concetta Quintarelli, PhD, Brigitte Strahm, MD, Waseem Qasim, MBBS PhD, Mary Slatter, Lorenzo Moretta, MD, Annemarie Moseley, MDPhD, Alice Bertaina, MDPhD

Blood (2015) 126 (23): 1931.

https://doi.org/10.1182/blood.V126.23.1931.1931

Published: 2015

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CLEC2A, a validated cancer-specific antigen, is an ideal candidate for immunotherapeutic targeting in KMT2A-rearranged AML

Fratricide-resistant anti-CD7 CAR-T cells for relapsed/refractory Acute Myeloid Leukemia

Phase I study of FH FOLR1 CAR T for pediatric patients with FOLR1+/CBFA2T3::GLIS2+ relapsed or refractory Acute Myeloid Leukemia

A novel B7-H3-specific binder enables effective CAR T-cell therapy in an Acute Myeloid Leukemia experimental model

CD19 antigen: From tumor target to safety switch able to improve the safety profile of CAR T cell therapy

Effective Dual Targeting of PRAME and WT1 with CD33-Gated ARTEMIS® Antibody-TCR Platform in Acute Myeloid Leukemia

Potent Target-Specific Efficacy of CAR T Cells Directed Toward the AML and KMT2A-Rearranged Specific Antigen CLEC2A

Phase I/II Clinical Trial on CD19-Chimeric Antigen Receptor (CAR) T Cells Generated with an Automated Process, from Fresh Apheresis, and Reinfused As Fresh Drug Product for Pediatric/Young Adult Patients with Relapsed/Refractory (r/r) B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

CD7.Pebl-CART for Patients with Relapsed/Refractory (r/r) T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia

Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL

CAR.CD123-NK Cells Have an Equally Effective but Safer Off-Tumor/on-Target Profile As Compared to CARCD123-T Cells for the Treatment of Acute Myeloid Leukaemia

Academic, Phase I/II Trial on T Cells Expressing a Second Generation, CD19-Specific Chimeric Antigen Receptor (CAR) and Inducible Caspase 9 Safety Switch for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL) in Children

A New Promising Third Generation CAR-CD30 T-Cell Therapy for CD30+ Lymphoma

CD19 Redirected CAR NK Cells Are Equally Effective but Less Toxic Than CAR T Cells

Alpha/Beta T-Cell and B-Cell Depletion HLA-Haploidentical Hematopoietic Stem Cell Transplantation Is an Effective Treatment for Children/Young Adults with Acute Leukemia

Patient-Derived Chimeric Antigen Receptor T-Cell Production Based on a Gammaretroviral Vector Platform Is Not Associated with Generation of CAR+ Leukemia Blasts

Phase I-IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in Relapsed/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM)

T-Cell Depleted HLA-Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (haplo-HSCT) Followed By Donor Lymphocyte Infusion with T Cells Transduced with the Inducible Caspase 9 (iC9) Suicide Gene in Children with Hematological Malignancies

Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Results of a Phase I-II Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only